These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 20731474)

  • 1. Opioid formulations designed to resist/deter abuse.
    Raffa RB; Pergolizzi JV
    Drugs; 2010 Sep; 70(13):1657-75. PubMed ID: 20731474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
    Bannwarth B
    Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?
    Raffa RB; Taylor R; Pergolizzi JV
    Expert Opin Drug Saf; 2014 Feb; 13(2):181-90. PubMed ID: 24206269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond.
    Ruan X
    Expert Opin Pharmacother; 2011 May; 12(7):999-1001. PubMed ID: 21470064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
    Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
    Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The implications of tamper-resistant formulations for opioid rotation.
    Pappagallo M; Sokolowska M
    Postgrad Med; 2012 Sep; 124(5):101-9. PubMed ID: 23095430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.
    Smith HS
    Expert Opin Pharmacother; 2011 May; 12(7):1111-25. PubMed ID: 21470065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature.
    Ruan X; Chen T; Gudin J; Couch JP; Chiravuri S
    J Opioid Manag; 2010; 6(4):300-3. PubMed ID: 20862910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
    Fanelli A; Sorella MC; Ghisi D
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.
    Badalamenti VC; Buckley JW; Smith ET
    J Opioid Manag; 2012; 8(2):115-25. PubMed ID: 22616317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?
    Schneider JP; Matthews M; Jamison RN
    CNS Drugs; 2010 Oct; 24(10):805-10. PubMed ID: 20839893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
    Webster LR; Brewer R; Wang C; Sekora D; Johnson FK; Morris D; Stauffer J
    J Pain Symptom Manage; 2010 Nov; 40(5):734-46. PubMed ID: 21075272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
    Webster LR; Johnson FK; Stauffer J; Setnik B; Ciric S
    Drugs R D; 2011 Sep; 11(3):259-75. PubMed ID: 21902287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Formulation Advances in Extended-Release Medications for Pain Control.
    Jones MR; Carney MJ; Kaye RJ; Prabhakar A; Kaye AD
    Curr Pain Headache Rep; 2016 Jun; 20(6):36. PubMed ID: 27084375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
    Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
    Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
    J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
    Nalamachu S; Kopecky EA; Taylor R; Vaughn B; O'Connor M
    Curr Med Res Opin; 2016 Jul; 32(7):1311-7. PubMed ID: 27025986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.
    Davis MP
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):823-31. PubMed ID: 27253690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.